Asia Pacific Pharmaceutical Continuous Manufacturing Market to Grow at a CAGR of 10.5% to reach US$ 604.91 Million from 2020 to 2027

Asia Pacific, the pharmaceutical continuous manufacturing market, is anticipated to reach US$ 604.91 Mn in 2027 from US$ 274.10 Mn in 2019. The market is projected to grow with a CAGR of 10.5% from 2020-2027.

The pharmaceutical continuous manufacturing market is growing primarily due to the advantages offered by continuous manufacturing process. Restraining factor such as, low R&D funding by government in developing economies is likely to damage the growth of the market in the coming years. On the other hand, emerging markets is expected to have a positive impact on the growth of the Asia Pacific pharmaceutical continuous manufacturing market in the coming years.

Countries in Asia Pacific and South and Central America are emerging as attractive outsourcing locations for biopharmaceutical industries. Low manufacturing and operating costs in China and India are key factors driving the growth of pharmaceutical manufacturing market in the region. Recent growth in the biopharmaceutical industry in both China and India indicates  positive future outlook for the market. Moreover, the growing domestic Asia Pacific pharmaceutical continuous manufacturing market and its pipelines are further opening up new avenues for the contract manufacturers as well as generic drug manufacturing in the APAC.

China’s pipeline has shown rapid growth in recent years. According to the International Society for Pharmaceutical Engineering, in 2016, the China Food and Drug Administration (CFDA) registered around 200 new biological pharmaceuticals entering clinical trials. Continuous pharmaceutical manufacturing is expected to contribute to the overall industry’s growth, and mostly benefit early-stage drug innovators owing to error-free development procedure. Moreover, to meet the growing demand, many contract-based organizations are expanding their manufacturing capabilities, further boosting the growth of the market. For instance, In January 2020, STA Pharmaceutical Co., Ltd., – a subsidiary of WuXi AppTec opened a new large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in China. Thus, the emerging markets are likely to act as high potential growth and revenue generators in the pharmaceutical continuous manufacturing market.

Considering the geographic and economical operations between Asian countries and China, the countries are expected to witness the challenge of COVID-19. The outbreak of disease has severely affected the tourism industry, lead to supply chain disruptions and problems posed by the shortage of healthcare infrastructure in low-income countries. For preventing the spread of disease, restrictive measures have been taken in South Korea, Malaysia, Singapore, the Philippines, and India. COVID-19 outbreak is expected to have short- and long-term impacts in the region. Domestic startups backed by international funding have already started witnessing back out from investors putting the development of the products in jeopardy.

In 2019, the Japan accounted for the largest market share in Asia Pacific pharmaceutical continuous manufacturing market, and it is also expected to grow at a faster pace over the forecast period. Growing aging population, increase the demand for advanced manufacturing capabilities, and increased the number of new drug approvals are the key factors that are responsible for the highest revenue share of the region. Moreover, the government is focusing on easing the regulatory policies and thereby accelerating the development and approval of new drugs into the market. Hence, considering the mentioned factors, the pharmaceutical continuous manufacturing market is expected to grow at a significant pace in the US during the forecast period.

Rest of Asia Pacific Pharmaceutical Continuous Manufacturing Market Revenue and Forecasts to 2027 (US$ Mn)

ASIA PACIFIC PHARMACEUTICAL CONTINUOUS MANUFACTURING – MARKET SEGMENTATION

By Product

• Integrated Systems
• Semi-Continuous Systems
  • Continuous Granulators
  • Continuous Blenders
  • Continuous Compressors

  • Continuous Coaters
  • Continuous Dryers
  • Other Semi-Continuous Systems
• Controls

By Application

• End Product Manufacturing
  • Solid Dosage Manufacturing
  • Liquid Dosage Manufacturing
• API Manufacturing

By End-User

• Full Scale Manufacturing Companies
  • Pharmaceutical Companies
  • Contract Manufacturing Organizations
• R & D Departments
  • Contract Research Organizations
  • Research Institutes

By Geography

• Asia Pacific

• • China
  • Japan
  • India
  • Australia
  • South Korea

Company Profiles

• Powrex Corp
• ACG
• Cadmach Machinery Co. Pvt. Ltd
• Hosokawa Micron Group,
• THERMO FISHER SCIENTIFIC INC.

Asia Pacific Pharmaceutical Continuous Manufacturing Report Scope